Janssen Pharmaceutical Inc.
NEWS
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
Korea Economic Daily, published a story saying that Samsung Group was in talks to acquire Biogen. However, Samsung BioLogics stated in a regulatory filing yesterday that the rumor is not true.
Janssen Pharmaceutical has recently applied for Biologics License Application for its relapsed or refractory (r/r) multiple myeloma drug. Here’s all about it.
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
A TikTok video went “viral” in November, claiming that vaccine regretters should take complex “detox” baths featuring ingredients such as borax.
The approval was based on Phase II data from the PLEIADES study that showed patients treated with the combination therapy generated an overall response rate of 84.8%.
The CDC has shifted its recommendation on adults getting a booster COVID-19 vaccine to now include everyone ages 18 years and older.
JOBS
IN THE PRESS